Prof. Dr. Peter Riederer
- Fachbereich Neurowissenschaften
- Ort Würzburg, Deutschland
- Wahljahr 2007
Forschung
Peter Riederer hat sich durch viele wichtige Beiträge auf dem Gebiet der klinischen Neurochemie von neuropsychiatrischen Erkrankungen ausgezeichnet, von denen ein großer Teil an der Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie an der Universität Würzburg ausgeführt wurde. Er hat die Laboratorien der Klinischen Neurochemie am Ludwig-Boltzmann-Institut für Neurochemie/Neurobiologie der Neurologischen Abteilung des Pflegeheimes der Stadt Wien–Lainz (1971 – 1986) sowie an der Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie an der Universität in Würzburg (1986 bis heute) zu internationaler Bedeutung geführt. Dies spiegelt sich in der Meistzitierrate 2004 eines Chemikers in medizinischer Forschung wider. Er leistete wichtige wissenschaftliche Beiträge auf dem Gebiet der Ätiopathogeneseforschung neurodegenerativer Erkrankungen, von denen jene zu oxidativem Stress, Eisenakkumulation, Atmungskettendefizit, Aufklärung des Wirkmechanismus von Aminoadamantanen, Wirkung und Toxizität von Neuromelanin, Einführung des Prinzipes der Monoaminoxidase-B-Hemmung bei Parkinson-Krankheit sowie die Erforschung der Insulin/Insulinrezeptorkaskadenstörung bei Alzheimer Krankheit zukunftsweisend sind. Diese in unterschiedlichen Kooperationen ermittelten Forschungsergebnisse mündeten in der Hypothese der „Neuroprotektion“, die er 1983 – 1985 mitentwickelt hat und die er auch heute unter klinischen Bedingungen als möglich hält. Die erfolgreiche Übertragung der mannigfaltig erfolgreichen Studien zu präklinischer Neuroprotektion in den klinischen Alltag als mittelfristige Therapieoption ist sein wesentlicher gegenwärtiger Forschungsansatz.
Peter Riederer is distinguished for many important contributions in the field of clinical neurochemistry of neuropsychiatric disorders. The majority of these were made at the Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy in Wuerzburg. He has brought both the Laboratory of Neurochemistry at the Neurological Department, Vienna, Lainz, Austria (1971 – 1986) and the Clinical Neurochemistry at the Dept. Psychiatry, Psychosomatics and Psychotherapy in Wuerzburg, Germany (1986 until now) into world renowned institutions. This is reflected by numerous awards but especially by the fact that he was in 2004 the most quoted chemist in the field of medicine. He made major contributions in the field of research devoted to the etiopathogenesis of neurodegenerative disorders. Those aimed at elucidating mechanisms of oxidative stress, iron accumulation, respiratory chain activity deficiency, physiology and toxicity of neuromelanin, identification of the mechanism of action of aminoadamantanes, introduction of the clinical strategy of the monoamine oxidase type B inhibitor selegiline in Parkinson’s disease as well as the more recent research on insulin/insulin receptor cascade as pathogenetic principle of sporadic Alzheimer’s disease are regarded as future oriented. These in many successful cooperations generated results had been the basis for establishing the hypothesis of neuroprotection, which has been co-developed with others between 1983 and 1985. Clinical neuroprotection, he is convinced about this, is possible and a major issue to follow. The translation of preclinical neuroprotection proven in so many different experimental designs into clinical everyday therapeutic strategy for Parkinson’s Disease and Alzheimer’s Disease is, he thinks, the only therapeutic option that can be realized in the near future.
Peter Riederer is distinguished for many important contributions in the field of clinical neurochemistry of neuropsychiatric disorders. The majority of these were made at the Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy in Wuerzburg. He has brought both the Laboratory of Neurochemistry at the Neurological Department, Vienna, Lainz, Austria (1971 – 1986) and the Clinical Neurochemistry at the Dept. Psychiatry, Psychosomatics and Psychotherapy in Wuerzburg, Germany (1986 until now) into world renowned institutions. This is reflected by numerous awards but especially by the fact that he was in 2004 the most quoted chemist in the field of medicine. He made major contributions in the field of research devoted to the etiopathogenesis of neurodegenerative disorders. Those aimed at elucidating mechanisms of oxidative stress, iron accumulation, respiratory chain activity deficiency, physiology and toxicity of neuromelanin, identification of the mechanism of action of aminoadamantanes, introduction of the clinical strategy of the monoamine oxidase type B inhibitor selegiline in Parkinson’s disease as well as the more recent research on insulin/insulin receptor cascade as pathogenetic principle of sporadic Alzheimer’s disease are regarded as future oriented. These in many successful cooperations generated results had been the basis for establishing the hypothesis of neuroprotection, which has been co-developed with others between 1983 and 1985. Clinical neuroprotection, he is convinced about this, is possible and a major issue to follow. The translation of preclinical neuroprotection proven in so many different experimental designs into clinical everyday therapeutic strategy for Parkinson’s Disease and Alzheimer’s Disease is, he thinks, the only therapeutic option that can be realized in the near future.